High materiality7/10
Jazz Pharmaceuticals (JAZZ) PT Raised to $300 at Deutsche Bank
Why it may matterVerify against the original reporting
Price target increase indicates bullish view on JAZZ.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Deutsche Bank raises Jazz Pharmaceuticals (JAZZ) target to $300; current price is $260.23, suggesting upside if the target is achieved.
- Deutsche Bank lifts JAZZ PT to $300; price $260.23.
- Jazz Pharmaceuticals upside potential after target increase.
Key facts
- 01
Target: $300
- 02
Posted price: $260.23
- 03
Analyst firm: Deutsche Bank
- 04
Analyst: David Hoang
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.